Abstract

Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease with a complex and multifactorial etiology. Topical treatment remains the mainstay of therapy in AD and research in the pathogenesis of the disease led to the identification of aryl hydrocarbon receptor (AhR) as a target of a new topical treatment. AhR is an environment sensor highly expressed in the skin and a transcription factor with a key role in inflammatory and immune signaling networks.

Tapinarof, an AhR agonist, is a new nonsteroidal topical agent applied to treat AD and psoriasis. Clinical trials have demonstrated its rapid and durable efficacy, favorable safety, and long-term tolerability, with minimal-to-no systemic absorption in adults and children. To confirm its long-term safety and efficacy across patient populations, ongoing and future trials and real-life studies will be essential

.

Tapinarof, an AhR agonist, is a new nonsteroidal topical agent applied to treat AD and psoriasis. It Trials demonstrated its rapid and durable efficacy, favorable safety, and long-term tolerability, with minimal-to-no systemic absorption in adults and children.

To confirm its long-term safety and efficacy across patient populations, ongoing and future trials and real-life studies will be essential.

References

  1. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016;387:1109-1122. https://doi.org/10.1016/S0140-6736(15)00149-X.
  2. Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. Br J Dermatol 2021;184:304-309. https://doi.org/10.1111/bjd.19580.
  3. Neri I, Galeone C, Pelucchi C, et al. Atopic Dermatitis in Italian Pre-School Children: Literature Review of Epidemiological Data with a Focus on Disease Prevalence and Severity. Children (Basel) 2023;10:1629. https://doi.org/10.3390/children10101629.
  4. Neri I, Galli E, Baiardini I, et al. Implications of Atopic Dermatitis on the Quality of Life of 6-11 Years Old Children and Caregivers (PEDI-BURDEN). J Asthma Allergy 2023;16:383-396. https://doi.org/10.2147/JAA.S404350.
  5. Savva M, Papadopoulos NG, Gregoriou S, et al. Recent Advancements in the Atopic Dermatitis Mechanism. Front Biosci (Landmark Ed) 2024;29:84. https://doi.org/10.31083/j.fbl2902084.
  6. Facheris P, Jeffery J, Del Duca E, et al. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol 2023;20:448-474. https://doi.org/10.1038/s41423-023-00992-4.
  7. Mohammad S, Karim MR, Iqbal S, et al. Atopic dermatitis: Pathophysiology, microbiota, and metabolome - A comprehensive review. Microbiol Res 2024;281:127595. https://doi.org/10.1016/j.micres.2023.127595.
  8. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel; Chu DK, Schneider L, Asiniwasis RN, et al.; Patient Groups: Global Parents for Eczema Research; Capozza K; National Eczema Association; Begolka WS; Evidence in Allergy Group; Chu AWL, Zhao IX, Chen L, et al.; AAAAI/ACAAI Joint Task Force on Practice Parameters; Golden D, Shaker M, Bernstein JA, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol 2024;132:274-312. https://doi.org/10.1016/j.anai.2023.11.009.
  9. Galli E, Fortina AB, Ricci G, et al. Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP). Ital J Pediatr 2022;48:95. https://doi.org/10.1186/s13052-022-01278-7.
  10. Maiello N., Galli E. Inibitori topici della calcineurina e dermatite atopica: ritorno al futuro? Rivista di Immunologia e Allergologia Pediatrica 2021;(01):1-6.
  11. Müller S, Maintz L, Bieber T. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. Allergy 2024;79:1501-1515. https://doi.org/10.1111/all.16009.
  12. Kim JH, Samra MS. Moderate to severe atopic dermatitis in children: focus on systemic Th2 cytokine receptor antagonists and Janus kinase inhibitors. Clin Exp Pediatr 2024;67:64-79. https://doi.org/10.3345/cep.2022.00346.
  13. Harvey J, Lax SJ, Lowe A, et al. The long-term safety of topical corticosteroids in atopic dermatitis: a systematic review. Skin Health Dis. 2023;3:e268. https://doi.org/10.1002/ski2.268.
  14. Pena J, Zameza PA, Pixley JN, et al. A Comparison of Topical Corticosteroids and Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis. J Allergy Clin Immunol Pract 2023;11:1347-1359. https://doi.org/10.1016/j.jaip.2023.03.022.
  15. Chaudhary F, Lee W, Escander T, et al. Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches. J Biotechnol Biomed 2024;7:314-328. https://doi.org/10.26502/jbb.2642-91280155.
  16. Neavin DR, Liu D, Ray B, et al. The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases. Int J Mol Sci 2018;19:3851. https://doi.org/10.3390/ijms19123851.
  17. Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis. Int J Mol Sci 2019;20:5424. https://doi.org/10.3390/ijms20215424.
  18. Hwang J, Newton EM, Hsiao J, et al. Aryl hydrocarbon receptor/nuclear factor E2-related factor 2 (AHR/NRF2) signalling: A novel therapeutic target for atopic dermatitis. Exp Dermatol 2022;31:485-497. https://doi.org/10.1111/exd.14541.
  19. Cannon AS, Nagarkatti PS, Nagarkatti M. Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases. Int J Mol Sci 2021;23:288. https://doi.org/10.3390/ijms23010288.
  20. Kim HB, Um JY, Chung BY, et al. Aryl Hydrocarbon Receptors: Evidence of Therapeutic Targets in Chronic Inflammatory Skin Diseases. Biomedicines 2022;10:1087. https://doi.org/10.3390/biomedicines10051087.
  21. Dec M, Arasiewicz H. Aryl hydrocarbon receptor role in chronic inflammatory skin diseases: a narrative review. Postepy Dermatol Alergol 2024;41:9-19. https://doi.org/10.5114/ada.2023.135617.
  22. Bahman F, Choudhry K, Al-Rashed F, et al. Aryl hydrocarbon receptor: current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases. Front Immunol 2024;15:1421346. https://doi.org/10.3389/fimmu.2024.1421346.
  23. Wazir A, O’Toole EA. Itching for innovation: role of aryl hydrocarbon receptor agonists as a future therapy for atopic dermatitis. Clin Exp Dermatol 2024 Nov 21:llae502. https://doi.org/10.1093/ced/llae502.
  24. Keam SJ. Tapinarof Cream 1%: First Approval. Drugs 2022;82:1221-1228. https://doi.org/10.1007/s40265-022-01748-6. Erratum in: Drugs 2022;82:1345. https://doi.org/10.1007/s40265-022-01768-2. Erratum in: Drugs 2022;82:1433. https://doi.org/10.1007/s40265-022-01771-7.
  25. Tsuji G, Yamamura K, Kawamura K, et al. Novel Therapeutic Targets for the Treatment of Atopic Dermatitis. Biomedicines 2023;11:1303. https://doi.org/10.3390/biomedicines11051303.
  26. Eichenfield LF, Silverberg JI, Hebert AA, et al. Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis. J Dermatolog Treat 2024;35:2300354. https://doi.org/10.1080/09546634.2023.2300354.
  27. Silverberg JI, Boguniewicz M, Quintana FJ, et al. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a clinical review. J Allergy Clin Immunol 2024;154:1-10. https://doi.org/10.1016/j.jaci.2023.12.013.
  28. Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol 2019;80:89-98.e3. https://doi.org/10.1016/j.jaad.2018.06.047.
  29. Paller AS, Stein Gold L, Soung J, et al. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol 2021;84:632-638. https://doi.org/10.1016/j.jaad.2020.05.135.
  30. Igarashi A, Tsuji G, Fukasawa S, et al. Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials. J Dermatol 2024;51:1404-1413. https://doi.org/10.1111/1346-8138.17451.
  31. Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol 2024;91:457-465. https://doi.org/10.1016/j.jaad.2024.05.023.
  32. Gold LS, Del Rosso J, Ehst BD, et al. Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials. J Dermatolog Treat 2025;36:2444489. https://doi.org/10.1080/09546634.2024.2444489.
  33. Fardos M, Cheedalla N, Watson AR et al. Tapinarof in atopic dermatitis: A comprehensive scoping review of clinical efficacy and safety. JAAD Reviews 2025;3:69-77. Https://doi.org/10.1016/j.jdrv.2024.12.001.

Downloads

pdf
Authors

Elena Galli - Pediatric Allergy Unit, San Pietro Hospital-Fatebenefratelli, Rome, Italy

Bianca Laura Cinicola - Pediatric Unit, NESMOS Department, Sant’Andrea University Hospital, Sapienza University of Rome, Rome, Italy

Tiziana Maiello - Dipartimento della Donna, del Bambino e di Chirurgia generale e specialistica, Università degli Studi della Campania L. Vanvitelli, Italy

Pasquale Comberiati - Department of Clinical and Experimental Medicine, Section of Paediatrics, University of Pisa, Pisa, Italy

Francesca Cipriani - Pediatra di Libera Scelta, AUSL di Bologna, Italy

Beatrice Andrenacci - SC Pneumoinfettivologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy

Bianca Gragnoli - Department of Clinical and Experimental Medicine, Section of Paediatrics, University of Pisa, Pisa, Italy

Giampaolo Ricci - Alma Mater - University of Bologna, Italy

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

Copyright (c) 2025 Italian Journal of Pediatric Allergy and Immunology

How to Cite
Galli, E. ., Cinicola, B. L., Maiello, T., Comberiati, P. ., Cipriani, F., Andrenacci, B. ., Gragnoli, B. ., & Ricci, G. (2025). Tapinarof as a new topical treatment in atopic dermatitis. Italian Journal of Pediatric Allergy and Immunology, 39(2). https://doi.org/10.53151/2531-3916/2025-1074
  • Abstract viewed - 68 times
  • pdf downloaded - 25 times